Jardiance (Boehringer Ingelheim Pharmaceuticals, Inc.)


Welcome to the PulseAid listing for the Jardiance drug offered from Boehringer Ingelheim Pharmaceuticals, Inc.. This Sodium-Glucose Cotransporter 2 Inhibitor [EPC],Sodium-Glucose Transporter 2 Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Boehringer Ingelheim Pharmaceuticals, Inc.
NON-PROPRIETARY NAME: Empagliflozin
SUBSTANCE NAME: EMPAGLIFLOZIN
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Sodium-Glucose Cotransporter 2 Inhibitor [EPC],Sodium-Glucose Transporter 2 Inhibitors [MoA]
ROUTE: ORAL
DOSAGE FORM: TABLET, FILM COATED
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2014-08-01
END MARKETING DATE: 0000-00-00


Jardiance HUMAN PRESCRIPTION DRUG Details:

Item DescriptionJardiance from Boehringer Ingelheim Pharmaceuticals, Inc.
LABELER NAME: Boehringer Ingelheim Pharmaceuticals, Inc.
DEA SCHEDULE:
ACTIVE STRENGTH: 10(mg/1)
START MARKETING DATE: 2014-08-01
END MARKETING DATE: 0000-00-00
PRODUCT ID: 0597-0152_b7744339-9029-a63e-a2ac-a378af58281f
PRODUCT NDC: 0597-0152
APPLICATION NUMBER: NDA204629

Other EMPAGLIFLOZIN Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Boehringer Ingelheim Pharmaceuticals, Inc.Jardiance
Cardinal HealthJardiance